Home > Press > Increase patent revenue for oral and non oral drug delivery products
Abstract:
Examining the latest developments in nanomedicine and enhancing in vivo circulation time, extending dissolution kinetics, and improving delivery with drug-porous nanocarriers, lipid-based compounds and biologics.
With less than a month to go join SMi at their 9th annual Controlled Release conference that will once again lead the way in examining the latest developments in nanomedicine and featuring fresh presentations from companies including GlaxoSmithKline, Lundbeck, Merck Serono and Genzyme.
Controlled Release will allow delegates to meet and network with key decision makers from the top pharmaceutical companies, as well as discuss & debate current issues such as challenges in drug formulation for oral delivery - where are we and what are the prospects for the future, challenges and opportunities for delivering biologics to the CNS and solutions for dissolution testing of non-oral formulations.
Network with key presenters within the pharmaceutical industry that includes:
• Peter Timmins, Executive Director, Drug Products, Science and Technology, Bristol-Myers Squibb
• Mark Wilson, Director, Collaboration Management, GlaxoSmithkline
• Simon Holland, Director, Process Understanding & Control, GlaxoSmithKline
• Bernd Riebesehl, Principal Fellow, Parenteral Dosage Forms, Pharmaceutical and Analytical Development, Novartis
• Mostafa Nakach, Head of the Pharmaceutical Engineering Group, Sanofi-Aventis
• Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis
• Jonathan Brown, Senior Research Investigator, Bristol-Myers Squibb
• Tomas Landh, Director, Novo Nordisk
• Jan L. Powell, Director, Physiology, Shire HGT
• Lars Bauer, Senior Medical Director, Therapeutic Area CNS, UCB
• Karin Liltorp, Director, Preformulation, Lundbeck
####
For more information, please click here
Contacts:
Fateja Begum
Tel: +44 (0) 207 827 6184
Kellee Halliburton
Copyright © SMi Group
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Researchers develop artificial building blocks of life March 8th, 2024
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Researchers develop artificial building blocks of life March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Events/Classes
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||